SEC Form 4
------------

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

Instruction 1(b).	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response: 0.5				
		or Section 30(h) of the Investment Company Act of 1940					
1. Name and Address of Reporting Person <sup>*</sup> <u>Requadt Scott</u>		2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Talaris Therapeutics, Inc.</u> [ TALS ]	(Check	all applicab	,		
<u>rtequaat beott</u>				Director		10% Owner	
(Last) (First) (Middl	le)	3. Date of Earliest Transaction (Month/Day/Year)	X	Officer (giv below)	ve title	Other (specify below)	
C/O TALARIS THERAPEUTICS, INC.		07/29/2022		Chief	f Executive Officer		
570 S. PRESTON STREET							
(Street)		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joir	int/Group Filing (Check Applicable		
LOUISVILLE KY 4020	202		X	Form filed	d by One Reporting Person		
				Form filed by More than One Person		One Reporting	
(City) (State) (Zip)							

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	07/29/2022		Р		39,382	Α	\$4.25	508,680	D	
Common Stock								449,766	Ι	See Footnote <sup>(1)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. These shares are held by Requadt Family Limited Partnership. The Reporting Person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership. Remarks:

## /s/ Mary Kay Fenton,

08/02/2022

attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.